BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2014 2:00:00 PM | Browse: 1512 | Download: 1354
 |
Received |
|
2012-12-13 09:56 |
 |
Peer-Review Started |
|
2012-12-13 18:42 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2013-01-10 12:38 |
 |
Revised |
|
|
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2013-04-15 16:27 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2013-04-16 07:55 |
 |
Articles in Press |
|
|
 |
Edit the Manuscript by Language Editor |
|
2013-04-20 19:14 |
 |
Typeset the Manuscript |
|
2013-07-26 09:54 |
 |
Publish the Manuscript Online |
|
2013-07-31 09:53 |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Chemotherapy for cholangiocarcinoma: An update
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Natalia Ramírez-Merino, Santiago Ponce Aix and Hernán Cortés-Funes |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dr. Natalia Ramírez-Merino, Department of Medical Oncology, Clinica La Luz, C/ General Rodrigo 8, 28003 Madrid, Spain. narame2@gmail.com |
| Key Words |
Chemotherapy; Cholangiocarcinoma; Review; Oncology; Gemcitabine |
| Core Tip |
Cholangiocarcinomas (bile duct cancers) are an heterogeneous group of malignancies arising from the epithelial cells of the intrahepatic, perihilar and extrahepatic bile ducts. Leucovorin-modulated 5-fluorouracil, capecitabine monotherapy or single agent gemcitabine are reasonable options for patients with a borderline performance status. After progression in patients with an adequate performance status, active regimens that could be considered for second line treatment include gemcitabine plus capecitabine or erlotinib plus bevacizumab. |
| Publish Date |
2013-07-31 09:53 |
| Citation |
Ramírez-Merino N, Aix SP, Cortés-Funes H. Chemotherapy for cholangio- carcinoma: An update. World J Gastrointest Oncol 2013; 5(7): 171-176 |
| URL |
http://www.wjgnet.com/1948-5204/full/v5/i7/171.htm |
| DOI |
http://dx.doi.org/10.4251/wjgo.v5.i7.171 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.